September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
1 citations
,
January 2016 in “Open Forum Infectious Diseases” Retinoic acid is not linked to hair loss from fluconazole use.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
37 citations
,
September 2002 in “Acta pædiatrica” A cystic fibrosis patient developed Cushing's syndrome from a drug interaction between itraconazole and budesonide, which improved after stopping the medications.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
Diane and Androcur 10 improved acne and seborrhea in most women, and hirsutism and alopecia in about half.
December 2025 in “Lviv clinical bulletin” PRP therapy may help with ovarian issues and fertility, but more research is needed.
May 2024 in “Rossijskaâ oftalʹmologiâ onlajn” Early treatment with corticosteroids improved her eye condition significantly.
January 2025 in “American Journal of Translational Research” The combination therapy effectively treats infertility in PCOS without major side effects.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
7 citations
,
March 2013 in “Tetrahedron Letters” New method makes important drug ingredients more easily without needing extra purification steps.
6 citations
,
October 2001 in “British Journal of Ophthalmology” Intralesional cidofovir may be a viable treatment for conjunctival lesions in Melkersson-Rosenthal syndrome without systemic toxicity.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
January 2023 in “Yādgār.” COVID-19 vaccines are linked to menstrual changes in many women.
March 2024 in “Ukraïnsʹkij žurnal dermatologìï, venerologìï, kosmetologìï” Topical retinoids are important for treating acne effectively and safely.
3 citations
,
June 2024 in “Pharmacia” New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.
65 citations
,
December 2010 in “Current Pharmaceutical Biotechnology” TRPV1 is involved in pain, various body functions, and diseases, but targeting it for treatment is challenging.
3 citations
,
April 2016 in “Innovare Academic Sciences - Innovare Journal of Ayurvedic Sciences” Cyperus rotundus is effective and safe for treating various diseases.
17 citations
,
January 2012 in “European Journal of Pharmaceutics and Biopharmaceutics” Isoconazole nitrate stays effective in skin and hair follicles for up to two weeks after use.
7 citations
,
January 2025 in “Journal of Medicinal Chemistry” New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
November 2024 in “Advances in Pharmacology and Pharmacy” A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
22 citations
,
May 2016 in “Breast cancer research and treatment” Some patients using cold caps to prevent hair loss from chemotherapy got mild scalp injuries similar to frostbite.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
May 2023 in “Journal of contemporary medicine” Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
52 citations
,
February 2003 in “Archives of dermatology” 9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
February 2026 in “Macromolecular Bioscience” Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
October 2023 in “Open Repository of the University of Porto (University of Porto)”